Phase 1 Start

ONC: Phase1_Start: A Phase 1, Open-Label, Parallel-Group, Single-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Tacabrutideg in Participants With Moderate and Severe Hepatic Impairment

Name: Phase1_Start: A Phase 1, Open-Label, Parallel-Group, Single-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Tacabrutideg in Participants With Moderate and Severe Hepatic Impairment
Start: 2026-10-22
End: 2026-10-22

October 22, 2026. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date: October 22, 2026
Company: BeOne Medicines Ltd. (ONC)

BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 1 Start

Phase1_Start: A Phase 1, Open-Label, Parallel-Group, Single-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Tacabrutideg in Participants With Moderate and Severe Hepatic Impairment

October 22, 2026

ONC overview →

Company: BeOne Medicines Ltd. (ONC)

Other upcoming events for ONC

Phase 1 StartPhase1_Start: A Phase 1, Open-label, Single-dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sonrotoclax in Participants With Severe Hepatic Impairment

Oct 15, 2026